Home > Insider Trading > Filing (0000899243-21-042710)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1840233	Xilio Therapeutics Inc.	XLO	()	X0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1780602	Sv7 Impact Medicine Fund Lp	71 Kingsway London X0 WC2B 6ST		No	No	Yes	No
1889859	Llp Gp (Imf) Sv7	71 Kingsway London X0 WC2B 6ST		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-10-26	998,544	$0.00	998,544	No	4	C	Direct
Common Stock	Acquisiton	2021-10-26	998,544	$0.00	998,544	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-10-26	302,588	$0.00	1,301,132	No	4	C	Direct
Common Stock	Acquisiton	2021-10-26	302,588	$0.00	1,301,132	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-10-26	312,500	$16.00	1,613,632	No	4	P	Direct
Common Stock	Acquisiton	2021-10-26	312,500	$16.00	1,613,632	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	See footnote
No	4	C	Direct
No	4	C	Indirect	See footnote
No	4	P	Direct
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-10-26	9,486,166	$0.00	998,544	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-10-26	9,486,166	$0.00	998,544	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2021-10-26	2,874,595	$0.00	302,588	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2021-10-26	2,874,595	$0.00	302,588	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Indirect
No	4	C	Direct
No	4	C	Indirect

Footnotes

The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.